Head-To-Head Analysis: BioLife Solutions (NASDAQ:BLFS) & Brainsway (NASDAQ:BWAY)

BioLife Solutions (NASDAQ:BLFS) and Brainsway (NASDAQ:BWAY) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, institutional ownership, risk, analyst recommendations, dividends, valuation and profitability.

Analyst Ratings

This is a breakdown of current ratings and price targets for BioLife Solutions and Brainsway, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioLife Solutions	0	0	7	1	3.13
Brainsway	0	0	2	0	3.00

BioLife Solutions presently has a consensus target price of $31.29, indicating a potential upside of 21.26%. Brainsway has a consensus target price of $18.00, indicating a potential upside of 19.21%. Given BioLife Solutions’ stronger consensus rating and higher possible upside, research analysts plainly believe BioLife Solutions is more favorable than Brainsway.

Profitability

This table compares BioLife Solutions and Brainsway’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
BioLife Solutions	-5.39%	0.16%	0.14%
Brainsway	11.60%	8.97%	5.65%

Earnings & Valuation

This table compares BioLife Solutions and Brainsway”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioLife Solutions	$82.25 million	15.03	-$20.18 million	($0.12)	-215.00
Brainsway	$46.08 million	6.19	$2.92 million	$0.26	58.08

Brainsway has lower revenue, but higher earnings than BioLife Solutions. BioLife Solutions is trading at a lower price-to-earnings ratio than Brainsway, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

BioLife Solutions has a beta of 1.78, suggesting that its share price is 78% more volatile than the S&P 500. Comparatively, Brainsway has a beta of 1.34, suggesting that its share price is 34% more volatile than the S&P 500.

Institutional & Insider Ownership

93.2% of BioLife Solutions shares are held by institutional investors. Comparatively, 30.1% of Brainsway shares are held by institutional investors. 2.2% of BioLife Solutions shares are held by company insiders. Comparatively, 19.0% of Brainsway shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

BioLife Solutions beats Brainsway on 8 of the 15 factors compared between the two stocks.

About BioLife Solutions

BioLife Solutions, Inc. develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company’s products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies. It offers proprietary biopreservation media products, including HypoThermosol FRS and CryoStor Freeze Media that are formulated to mitigate preservation-induced, delayed-onset cell damage and death; bioproduction tools, such as human platelet lysates for cell expansion and CellSeal closed system vials that are used in CGT; and the ThawSTAR line that comprises of a family of automated thawing devices for frozen cell and gene therapies packaged in cryovials and cryobags. The company also provides cryogenic freezer technology for controlled rate freezing and cryogenic storage of biologic materials; ultra-low temperature mechanical freezers; evo shipping containers that are cloud-connected passive storage and transport containers for temperature-sensitive biologics and pharmaceuticals; liquid nitrogen laboratory freezers, cryogenic equipment, and accessories; and biological and pharmaceutical storage and transport services. It markets and sells its products directly, as well as through third party distributors. The company was incorporated in 1987 and is headquartered in Bothell, Washington.

About Brainsway

BrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson's diseases. The company serves doctors, hospitals, and medical centers in the field of psychiatry. BrainsWay Ltd. was founded in 2003 and is headquartered in Jerusalem, Israel.